Current pharmacotherapy for weight loss: A review and implications for plastic surgeons

Aesthetic Surgery Journal

Volumn 21, Issue 2, 2001, Pages 142-146

  Giese, Sharon Y ^a   Neborsky, Rebecca ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0035284977     PISSN: 1090820X     EISSN: None     Source Type: Journal    
DOI: 10.1067/maj.2001.114450     Document Type: Article

References (15)

1. 1. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999;282:1519-1522.
2. 2. Carek PJ, et al. Current concepts in the pharmacological management of obesity. Drugs 1999;157:883-904.
3. 3. Lean M. Subutramine - a review of clinical efficacy. Int J Obes Relat Metab Disord 1997;21(Suppl):530-536.
4. 4. Drug Evaluation Monographs. Vol. 101. Micromedex Inc.; 1999;.
5. 5. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-713.
6. 6. Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract 1999;49:871-4.
7. 7. Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: a double blind trial. Int J Obes Relat Metab Disord 1992;16:269-277.
8. 8. Kam PC, Chang GW. Selective serotonin reuptake inhibitors: pharmacology and clinical implications in anesthesia and critical care medicine. Anesthesia 1997;52:982-988.
9. 9. Heck AM, Yanovski JA, Kalis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000;20:270-9.
10. 10. Giese S. The phen-fen no-no with general anesthesia. Plast Reconstr Surg 1998;101:552-553.
11. 11. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343:1826-1832.
12. 12. Goldstein DJ, Rampey AH, Roback OJ, et al. Efficacy and safety of long-tern fluoxetine treatment of obesity - maximizing success. Obes Res 1995;3(suppl):481S-490S.
13. 13. Haycock B. Pharmacological approaches to fat loss: targeting betaadrenergic receptors. Mesomorphosis 1998 July;1(2). Online publication. Available at: http://www.meso-rx.com/articles/haycock/ ephedrine-and-beta-adrenergic-receptors.htm. Last accessed January 18, 2001.
14. 14. Gurley BJ, Gardner SF, White LM, Wang PL. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang). Ther Drug Monit 1998;20:439-445.
15. 15. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;345:1833-1838.